203 related articles for article (PubMed ID: 23528604)
1. Nanosuspension for parenteral delivery of a p-terphenyl derivative: preparation, characteristics and pharmacokinetic studies.
Tian X; Li H; Zhang D; Liu G; Jia L; Zheng D; Shen J; Shen Y; Zhang Q
Colloids Surf B Biointerfaces; 2013 Aug; 108():29-33. PubMed ID: 23528604
[TBL] [Abstract][Full Text] [Related]
2. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
[TBL] [Abstract][Full Text] [Related]
3. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability.
Xia D; Quan P; Piao H; Piao H; Sun S; Yin Y; Cui F
Eur J Pharm Sci; 2010 Jul; 40(4):325-34. PubMed ID: 20417274
[TBL] [Abstract][Full Text] [Related]
4. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
[TBL] [Abstract][Full Text] [Related]
5. Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.
Yuan H; Li X; Zhang C; Pan W; Liang Y; Chen Y; Chen W; Liu L; Wang X
Drug Deliv; 2016 Oct; 23(8):2772-2779. PubMed ID: 26292058
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of freeze-dried 2-methoxyestradiol nanoparticle powders.
Du B; Li XT; Zhao Y; A YM; Zhang ZZ
Pharmazie; 2010 Jul; 65(7):471-6. PubMed ID: 20662313
[TBL] [Abstract][Full Text] [Related]
7. Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability.
Shen G; Cheng L; Wang LQ; Zhang LH; Shen BD; Liao WB; Li JJ; Zheng J; Xu R; Yuan HL
Chin J Nat Med; 2016 Oct; 14(10):757-768. PubMed ID: 28236405
[TBL] [Abstract][Full Text] [Related]
8. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.
Li W; Yang Y; Tian Y; Xu X; Chen Y; Mu L; Zhang Y; Fang L
Int J Pharm; 2011 Apr; 408(1-2):157-62. PubMed ID: 21295124
[TBL] [Abstract][Full Text] [Related]
9. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
Karakucuk A; Celebi N; Teksin ZS
Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
[TBL] [Abstract][Full Text] [Related]
10. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension.
Wang Y; Liu Z; Zhang D; Gao X; Zhang X; Duan C; Jia L; Feng F; Huang Y; Shen Y; Zhang Q
Colloids Surf B Biointerfaces; 2011 Apr; 83(2):189-97. PubMed ID: 21176876
[TBL] [Abstract][Full Text] [Related]
11. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
12. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability.
Ige PP; Baria RK; Gattani SG
Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990
[TBL] [Abstract][Full Text] [Related]
13. Studies on pharmacokinetics and tissue distribution of bifendate nanosuspensions for intravenous delivery.
Liu Y; Zhang D; Duan C; Jia L; Xie P; Zheng D; Wang F; Liu G; Hao L; Zhang X; Zhang Q
J Microencapsul; 2012; 29(2):194-203. PubMed ID: 22172025
[TBL] [Abstract][Full Text] [Related]
14. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM
Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297
[TBL] [Abstract][Full Text] [Related]
15. Development of a chemically stable 10-hydroxycamptothecin nanosuspensions.
Pu X; Sun J; Wang Y; Wang Y; Liu X; Zhang P; Tang X; Pan W; Han J; He Z
Int J Pharm; 2009 Sep; 379(1):167-73. PubMed ID: 19505545
[TBL] [Abstract][Full Text] [Related]
16. Preparation of azithromycin nanosuspensions by reactive precipitation method.
Hou CD; Wang JX; Le Y; Zou HK; Zhao H
Drug Dev Ind Pharm; 2012 Jul; 38(7):848-54. PubMed ID: 22092042
[TBL] [Abstract][Full Text] [Related]
17. Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation.
Chen L; Wang Y; Zhang J; Hao L; Guo H; Lou H; Zhang D
Eur J Pharm Biopharm; 2014 May; 87(1):160-9. PubMed ID: 24333772
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization and in vivo evaluation of amorphous tacrolimus nanosuspensions produced using CO2-assisted in situ nanoamorphization method.
Wang Y; Han X; Wang J; Wang Y
Int J Pharm; 2016 May; 505(1-2):35-41. PubMed ID: 27034003
[TBL] [Abstract][Full Text] [Related]
19. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies.
Zhang D; Tan T; Gao L; Zhao W; Wang P
Drug Dev Ind Pharm; 2007 May; 33(5):569-75. PubMed ID: 17520449
[TBL] [Abstract][Full Text] [Related]
20. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]